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Background
Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety 
of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as com-
pared with the best available therapy, in patients with myelofibrosis.
Methods
We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, 
post–polycythemia vera myelofibrosis, or post–essential thrombocythemia myelofi-
brosis to receive oral ruxolitinib or the best available therapy. The primary end point 
and key secondary end point of the study were the percentage of patients with at least 
a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed 
with the use of magnetic resonance imaging or computed tomography.
Results
A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in 
spleen volume at week 48, as compared with 0% in the group receiving the best avail-
able therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% 
(P<0.001). At 48 weeks, the mean palpable spleen length had decreased by 56% with 
ruxolitinib but had increased by 4% with the best available therapy. The median dura-
tion of response with ruxolitinib was not reached, with 80% of patients still having a 
response at a median follow-up of 12 months. Patients in the ruxolitinib group had 
an improvement in overall quality-of-life measures and a reduction in symptoms as-
sociated with myelofibrosis. The most common hematologic abnormalities of grade 
3 or higher in either group were thrombocytopenia and anemia, which were managed 
with a dose reduction, interruption of treatment, or transfusion. One patient in each 
group discontinued treatment owing to thrombocytopenia, and none discontinued ow-
ing to anemia. Nonhematologic adverse events were rare and mostly grade 1 or 2. Two 
cases of acute myeloid leukemia were reported with the best available therapy.
Conclusions
Continuous ruxolitinib therapy, as compared with the best available therapy, was 
associated with marked and durable reductions in splenomegaly and disease-related 
symptoms, improvements in role functioning and quality of life, and modest toxic ef-
fects. An influence on overall survival has not yet been shown. (Funded by Novartis 
Pharmaceuticals; ClinicalTrials.gov number, NCT00934544.)
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Myelofibrosis, which can present as a primary disease or can evolve from polycythemia vera or essential thrombo-
cythemia,1 is characterized by marrow fibrosis, 
progressive anemia, and extramedullary hemato-
poiesis, manifested primarily as splenomegaly. 
Severe constitutional symptoms (e.g., night sweats 
and weight loss), pruritus, fatigue, and sequelae of 
splenomegaly are common.2 The median survival 
from the time of diagnosis is 4 years for patients 
with intermediate-2–risk disease and 2 years for 
patients with high-risk disease.3 Apart from al-
logeneic stem-cell transplantation, treatment is 
palliative and does not address the characteristic 
abnormality identified in myelofibrosis, a dysreg-
ulation of Janus kinase (JAK)–mediated cytokine 
and growth-factor signal transduction.4
In 2005, the JAK2 V617F mutation was identi-
fied as the most common molecular abnormality 
in myeloproliferative neoplasms.5-8 Other muta-
tions that activate the JAK pathway have been 
identified, including mutations in JAK2 exon 12, 
myeloproliferative leukemia virus oncogene (MPL), 
and LNK.9-11 Thus, dysregulation of the JAK signal-
ing pathway is frequently noted in patients who 
have myelofibrosis, with or without the V617F mu-
tation.12
Ruxolitinib (also known as INC424 or 
INCB18424) is an orally bioavailable, potent, and 
selective inhibitor of JAK1 and JAK2 that is ap-
proved for the treatment of intermediate- and high-
risk myelofibrosis.13,14 Ruxolitinib selectively in-
hibits the proliferation of JAK2 V617F-driven Ba/F3 
cells, and these effects are correlated with de-
creased levels of phosphorylated JAK2 and of 
signal transducer and activator of transcription 
5 (STAT5).13 In a phase 1–2 study of patients with 
myelofibrosis, ruxolitinib was associated with 
weight gain, prompt and marked reductions in 
spleen size, and reductions in debilitating symp-
toms.15 We describe here results from the Con-
trolled Myelofibrosis Study with Oral JAK Inhibi-
tor Treatment II (COMFORT-II), a randomized, 
phase 3 trial comparing ruxolitinib with the best 
available therapy in patients with primary myelo-
fibrosis, post–polycythemia vera myelofibrosis, or 
post–essential thrombocythemia myelofibrosis.
Me thods
Eligibility Criteria
Patients 18 years of age or older who had primary 
myelofibrosis, post–polycythemia vera myelofibro-
sis, or post–essential thrombocythemia myelofi-
brosis16 and a palpable spleen 5 cm or more below 
the costal margin were eligible for the study, irre-
spective of their JAK2 V617F mutation status. Eligi-
ble patients had two prognostic factors (interme-
diate-2 risk) or three or more prognostic factors 
(high risk) according to the International Prognos-
tic Scoring System (in which the prognostic factors 
are age >65 years, hemoglobin level of <10 g per 
deciliter, leukocyte count of >25×109 per liter, 
≥1% circulating myeloblasts, and presence of 
constitutional symptoms),3 a peripheral-blood 
blast count of less than 10%, a platelet count of 
100×109 or more per liter, an Eastern Cooperative 
Oncology Group (ECOG) performance status17 of 
3 or less (on a scale from 0 to 5, with 0 indicating 
that the patient is fully active, higher scores indi-
cating increasing disability, and 5 indicating death; 
see Table 1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org), 
and no prior treatment with a JAK inhibitor. In ad-
dition, eligible patients were not considered to be 
suitable candidates for allogeneic stem-cell trans-
plantation at the time of enrollment.
Study Design
Patients were stratified according to prognostic 
score3 at enrollment and were randomly assigned, 
in a 2:1 ratio, to receive ruxolitinib or the best avail-
able therapy, which included any commercially 
available agents (as monotherapy or in combina-
tion) or no therapy at all and which could be 
changed during the treatment phase. The starting 
dose of ruxolitinib tablets was 15 mg twice daily 
if the baseline platelet count was 200×109 per liter 
or less and 20 mg orally twice daily if the baseline 
platelet count was greater than 200×109 per liter. 
A protocol-specified dosing regimen required re-
ductions of the dose for reasons of safety (if neu-
tropenia or thrombocytopenia developed) and 
permitted escalation of the dose to increase ef-
ficacy, although the dose could not exceed 25 mg 
twice daily.15 Patients received ruxolitinib or the 
best available therapy until the criteria for disease 
progression were met. At any time, patients who 
met protocol-specified criteria (underwent sple-
nectomy or had an increase in spleen volume of 
>25% from the nadir during the study period, 
which could include the baseline volume) discon-
tinued the randomized treatment phase of the 
study and could enter an extension phase. In the 
extension phase, patients who had been randomly 
assigned to the best available therapy could re-
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ceive ruxolitinib if they met protocol-specified 
safety criteria, and patients who had been random-
ly assigned to ruxolitinib could continue to receive 
ruxolitinib if they were still deriving a clinical ben-
efit. Patients who had leukemic transformation 
or underwent splenic irradiation were withdrawn 
from the study.
End Points
The primary end point was a reduction of 35% 
or more in spleen volume from baseline at week 
48. This end point was selected on the basis of the 
international response criterion of a reduction of 
50% or more in spleen length as assessed by pal-
pation18 and prior data showing a correlation of 
that measurement with a 33% reduction in spleen 
volume as measured by magnetic resonance im-
aging (MRI).15 Spleen volume was assessed by MRI 
or by computed tomography (CT) (in the case of 
patients who were not suitable candidates for MRI) 
every 12 weeks; the images were read by a reader at 
a central location who was unaware of the group 
assignments. Spleen and liver volumes were as-
sessed by outlining the circumference of the organ 
and determining the volume using a least-squares 
analysis. Spleen length was assessed by manual pal-
pation at every study visit. Throughout this report, 
measurements of spleen volume were performed 
by MRI or CT, whereas measurements of spleen 
length were performed by palpation.
The key secondary end point was a reduction of 
35% or more in spleen volume from baseline at 
week 24. Additional secondary end points included 
the length of time that a reduction in spleen vol-
ume of at least 35% was maintained, the time to a 
reduction in spleen volume of 35% or more from 
baseline, progression-free survival, leukemia-free 
survival, overall survival, and change in marrow 
histomorphologic features. Information regarding 
other secondary and exploratory end points and 
the definition of disease progression are provided 
in the Supplementary Appendix.
Symptoms and Quality of Life
Symptoms and quality of life were assessed with 
the use of the European Organization for Research 
and Treatment of Cancer (EORTC) quality-of-life 
questionnaire core model (QLQ-C30) and the Func-
tional Assessment of Cancer Therapy–Lymphoma 
(FACT-Lym) scale. The EORTC QLQ-C30 includes 
five scales related to functioning, nine scales re-
lated to symptoms, and a global health status 
and quality-of-life scale. The FACT-Lym consists 
of a general core questionnaire (FACT-G), a dis-
ease-specific questionnaire (Lymphoma Subscale 
[LymS]), and a trial outcome index (FACT-TOI), 
which is a summary index of physical, functional, 
and symptom outcomes.
Safety
The safety population consisted of all patients in 
the ruxolitinib group who received at least one dose 
of study drug and all patients in the best-available-
therapy group. Adverse events were monitored con-
tinuously during the study and were graded accord-
ing to the National Cancer Institute’s Common 
Toxicity Criteria, version 3. Throughout the study, 
patients provided blood samples at specified times, 
and the samples were analyzed by the same labo-
ratory throughout the study to ensure consistency 
in values.
Study Oversight
The study was sponsored by Novartis Pharmaceu-
ticals and designed by Incyte. It was approved by 
the institutional review board at each participating 
institution, and was conducted in accordance with 
the principles of the Declaration of Helsinki. All 
patients provided written informed consent. Data 
were analyzed and interpreted by the sponsor’s 
clinical and statistical teams in collaboration with 
authors who were not affiliated with the sponsor. 
An independent data and safety monitoring board 
reviewed the trial data and made recommendations 
regarding the continuation of the study. The first 
author prepared the first draft of the manuscript, 
with assistance from a medical writer who was 
funded by Novartis Pharmaceuticals, and made the 
final decision to submit the manuscript for publi-
cation. All the authors and representatives of the 
sponsor reviewed and amended the manuscript. 
All the authors vouch for the accuracy and com-
pleteness of the data and verify that the study as 
reported conforms to the protocol and statistical 
analysis plan (both of which are available at 
NEJM.org).
Statistical Analysis
The efficacy analysis was performed according to 
the intention-to-treat principle, with data from all 
patients who underwent randomization. The data-
base cutoff date was January 4, 2011, the date on 
which the last patient completed the week 48 study 
visit. Patients who did not undergo an assessment 
of spleen volume at week 48 were considered not 
to have had a response. The two groups were com-
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pared with the use of the exact Cochran–Mantel–
Haenszel test, stratified according to prognostic 
category (intermediate-2 risk or high risk). The 
family-wise alpha level was controlled at 0.05 over-
all for two prespecified comparisons (the primary 
and key secondary end points). The key secondary 
end point was to be tested only if the primary end 
point showed significance at a two-sided alpha 
level of 0.05. No formal adjustment for multiple 
comparisons has been made. Survival curves for 
leukemia-free survival, overall survival, and pro-
gression-free survival were estimated with the use 
of the Kaplan–Meier method. Hazard ratios and 
the corresponding 95% confidence intervals were 
estimated with the use of the Cox proportional-
hazards model, stratified according to baseline 
prognostic category; the between-group treatment 
difference was tested with the use of a stratified 
two-sided log-rank test.
R esult s
Characteristics of the Patients
During the period from July 1, 2009, through Jan-
uary 22, 2010, a total of 219 patients underwent 
randomization, of whom 146 were assigned to re-
ceive ruxolitinib and 73 were assigned to receive 
the best available therapy. The baseline charac-
Table 1. Baseline Characteristics of the Study Patients.*
Characteristic
Ruxolitinib 
(N = 146)
Best Available Therapy 
(N = 73)
Age (yr)
Median 67 66
Range 35–83 35–85
Sex (%)
Male 57 58
Female 43 42
Risk category (%)†
Intermediate-2 40 40
High 60 59
Not determined 0 1
ECOG performance status (%)‡
0 40 36
1 53 51
2 7 12
3 1 1
Myelofibrosis subtype (%)
Primary 53 53
Post–polycythemia vera 33 27
Post–essential thrombocythemia 14 19
Previous myelofibrosis therapy (%) 76 73
Hydroxyurea 75 68
Radiotherapy 0 5
Palpable spleen length below costal margin (cm)
Median 14 15
Range 5–30 5–37
Spleen volume (cm3)§
Median 2408 2318
Range 451–7766 728–7701
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teristics were balanced between the groups (Ta-
ble 1). Approximately half the patients had pri-
mary myelofibrosis, approximately one third had 
post–polycythemia vera myelofibrosis, and the re-
mainder had post–essential thrombocythemia my-
elofibrosis. Approximately 40% of the patients in 
each study group were classified as having disease 
of intermediate-2 risk, and 60% were classified as 
having high-risk disease.
Treatment with ruxolitinib was initiated at a 
dose of 15 mg twice daily in 38% of the patients 
and at a dose of 20 mg twice daily in 62%. The 
median dose intensity of ruxolitinib was 30 mg per 
day (range, 10 to 49). Among patients receiving the 
best available therapy, the most common therapies 
were antineoplastic agents (in 51%) — most fre-
quently hydroxyurea (47%) — and glucocorticoids 
(16%); a total of 33% of patients received no thera-
py (Table 2 in the Supplementary Appendix). As of 
the data cutoff date (January 4, 2011), a smaller 
percentage of patients in the ruxolitinib group 
than in the best-available-therapy group had dis-
continued the randomized treatment phase of the 
study (38% vs. 58%). Of the 55 patients who had 
been randomly assigned to receive ruxolitinib and 
who discontinued the randomized treatment phase 
owing to protocol-specified criteria, 29 (53%) en-
tered the extension phase and continued to receive 
ruxolitinib because they were still deriving clinical 
benefits. Of the 42 patients who had originally 
been assigned to receive the best available therapy 
and who discontinued the randomized treatment 
phase for any reason, 18 (43%) met protocol-
specified criteria for crossover to ruxolitinib in the 
extension phase. Information on patient disposi-
tion is provided in Figure 1 and Table 3 in the 
Supplementary Appendix. The data included in this 
article are those from the randomized treatment 
phase only.
Efficacy Analysis
Assessments of Spleen Volume and Length
The efficacy analyses included all 219 patients who 
underwent randomization (146 in the ruxolitinib 
group and 73 in the group receiving the best 
available therapy). Three patients (two in the rux-
olitinib group and one in the group receiving the 
best available therapy) underwent baseline MRI 
Table 1. (Continued.)
Characteristic
Ruxolitinib
(N = 146)
Best Available Therapy
(N = 73)
Presence of constitutional symptoms (%)¶ 69 63
Hemoglobin <10 g/dl (%) 45 52
Median neutrophil count (×10−9/liter) 11.3 9.4
Median platelet count (×10−9/liter) 244 228
History of leukocyte count >25×109/liter (%) 38 36
Circulating blasts ≥1% (%) 76 74
JAK2 V617F mutation status at screening (%)
Positive 75 67
Negative 24 27
Unknown 1 6
* There were no significant differences between the two groups in any of the baseline characteristics listed here.
† Risk was classified as “not determined” if any one of the five International Prognostic Scoring System risk factors (age  
>65 years, hemoglobin level <10 g per deciliter, leukocyte count >25x109 per liter, ≥1% circulating myeloblasts, and 
presence of constitutional symptoms) was not available. No data on assessment of prognostic factors were entered  
for one patient in the best-available-therapy group.
‡ The Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5. An ECOG status of 0 indi-
cates that the patient is fully active and able to carry on all predisease activities without restriction, 1 indicates that the 
patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light or sedentary 
nature (e.g., light housework or office work), 2 indicates that the patient is ambulatory and capable of all self-care but 
unable to carry out any work activities and is up and about more than 50% of waking hours, and 3 indicates that the 
patient is capable of only limited self-care and is confined to a bed or chair more than 50% of waking hours.
§ The median normal spleen volume is approximately 200 cm3.
¶ Constitutional symptoms included weight loss, fever, and night sweats.
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assessments of spleen volume after randomization 
and were not included in the efficacy analyses of 
spleen volume. At week 48, most of the patients in 
the ruxolitinib group had a reduction in spleen vol-
ume (Fig. 1A). Only patients in the ruxolitinib 
group met the criterion for the primary end point, 
at least a 35% reduction in spleen volume from 
baseline at 48 weeks (28%, vs. 0% in the group re-
ceiving the best available therapy; P<0.001). Simi-
larly, only patients in the ruxolitinib group met the 
criterion for the key secondary end point: a reduc-
tion of at least 35% in spleen volume at 24 weeks 
(32%, vs. 0% in the group receiving the best avail-
able therapy; P<0.001).
Analyses of prespecified exploratory end points 
showed that there were significant differences in 
the mean percentage change in spleen volume from 
baseline between the group assigned to ruxolitinib 
and the group assigned to the best available thera-
py, at week 24 (−29.2% vs. 2.7%, P<0.001) and at 
week 48 (−30.1% vs. 7.3%, P<0.001). During the 
48-week period, almost all patients who were 
treated with ruxolitinib (97%), as compared with 
56% given the best available therapy, had a measur-
able reduction in spleen volume (Fig. 1B). Among 
the 136 patients in the ruxolitinib group and 63 in 
the best-available-therapy group who had a base-
line measurement and at least one subsequent 
measurement, only 4 patients (3%) in the ruxoli-
tinib group — 3 of whom were V617F-positive — 
as compared with 28 (44%) in the group receiving 
the best available therapy had an increase in 
spleen volume as the best percentage change 
from baseline.
In secondary analyses, reductions in spleen 
volume with ruxolitinib were seen across all patient 
subgroups, including subgroups defined accord-
ing to sex, myelofibrosis subtype, and prognostic 
category (all prespecified analyses) and JAK2 V617F 
mutation status (a post hoc analysis). The rates of 
response (i.e., reduction in spleen volume of ≥35%) 
in the V617F-positive subgroup were 33% (95% 
confidence interval [CI], 25 to 43) with ruxolitinib 
and 0% (95% CI, 0 to 7) with the best available 
therapy; the corresponding rates in the V617F-
negative subgroup were 14% (95% CI, 5 to 30) and 
0% (95% CI, 0 to 17).
Prespecified secondary analyses also showed 
that ruxolitinib resulted in rapid and durable re-
ductions in spleen volume. The median time to the 
first observation on MRI or CT of a reduction from 
baseline of 35% or more in spleen volume was 
12.3 weeks in the ruxolitinib group (Table 4 in 
the Supplementary Appendix). Among the 69 pa-
tients who had a reduction in spleen volume of 
at least 35% at any time during the study, the 
reduction was observed at the first assessment 
(12 weeks) in 44 patients (64%). The median du-
ration of response among patients treated with 
ruxolitinib was not reached, with 80% of patients 
still having a response at a median of 12 months 
of follow-up (Fig. 1C). Only 1 patient who received 
the best available therapy had a reduction of at 
least 35% in spleen volume at week 12, but data 
from that patient could not be assessed further 
owing to censoring.
At the first prespecified assessment of palpa-
ble spleen length (week 4), the mean length had 
decreased from baseline in patients receiving rux-
olitinib but had increased in patients receiving the 
best available therapy (Fig. 1D). At week 48, pa-
tients treated with ruxolitinib had a mean decrease 
in spleen length from baseline of 56%, as com-
pared with a mean increase of 4% in patients re-
ceiving the best available therapy.
Survival Assessments
By the data cutoff date at a median of 12 months 
of follow-up, 124 patients who had been randomly 
assigned to the ruxolitinib group and 50 patients 
who had been randomly assigned to the best-avail-
able-therapy group were alive and still being fol-
lowed for the prespecified secondary survival end 
points beyond 48 weeks. In a time-to-event analy-
sis, conducted at week 48, there were 44 patients in 
the ruxolitinib group (30%) who had progression 
events, as compared with 19 (26%) in the group 
receiving the best available therapy (hazard ratio 
for progression with ruxolitinib, 0.81; 95% CI, 
0.47 to 1.39). In the analyses of leukemia-free sur-
vival and overall survival, there were 10 events in 
total (all of which were deaths): 6 events (4%) with 
ruxolitinib, as compared with 4 events (5%) with the 
best available therapy (hazard ratio for leukemia-
free survival with ruxolitinib, 0.65; 95% CI, 0.18 to 
2.31; hazard ratio for overall survival, 0.70; 95% CI, 
0.20 to 2.49). In an analysis performed for a 
planned safety update with approximately 2 months 
of additional follow-up (median, 61.1 weeks), a 
total of 11 deaths (8%) were reported in the rux-
olitinib group and 4 (5%) in the group receiving 
the best available therapy (hazard ratio, 1.01; 95% 
CI, 0.32 to 3.24). The median survival time has 
not been reached. The study was not powered to 
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detect differences in time-to-event end points, and 
a limited number of patients remain in the group 
receiving the best available therapy for further 
time-to-event end-point analyses.
Marrow Histomorphologic and Biomarker 
Assessments
No major changes in marrow histomorphologic 
features were observed in a prespecified secondary 
analysis of data from patients receiving any therapy. 
In a prespecified exploratory analysis, ruxolitinib 
treatment was associated with changes in plasma 
biomarkers (Table 5 in the Supplementary Appen-
dix); levels of several proinflammatory cytokines, 
including interleukin-6, tumor necrosis factor al-
pha, and C-reactive protein were reduced, whereas 
erythropoietin and leptin levels were increased.
Symptoms and Other Patient-Reported Outcomes
In prespecified exploratory analyses of patient-
reported outcomes (as assessed by means of the 
EORTC QLQ-C30 and FACT-Lym subscales), pa-
tients in the ruxolitinib group, as compared with 
patients receiving the best available therapy, had 
improved quality-of-life and role functioning (Fig. 
2A). At week 48, patients receiving ruxolitinib had 
marked reductions in myelofibrosis-associated 
symptoms, including appetite loss, dyspnea, fa-
tigue, insomnia, and pain, whereas patients re-
ceiving the best available therapy had worsening 
symptoms (Fig. 2B). Similarly, substantial improve-
ments in FACT-Lym scores indicated that patients 
receiving ruxolitinib had a reduction in myelofi-
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Figure 2. Changes in Quality-of-Life and Symptom-
Assessment Scores, According to Treatment Group.
Mean changes from baseline at week 48 are shown for 
scores on the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life question-
naire core model (QLQ-C30) global health status–quality 
of life and selected functioning scores (Panel A); selected 
EORTC QLQ-C30 symptom scores (Panel B); and 
Functional Assessment of Cancer Therapy–Lymphoma 
(FACT-Lym) scores, including total scores, disease- 
specific subscale (FACT-LymS) scores, Trial Outcome 
Index (FACT-TOI) scores (a summary of physical, func-
tional, and disease-specific outcomes), and general 
(FACT-G) scores (Panel C). In Panels A and C, improve-
ment is represented by positive numbers, whereas in 
Panel B, improvement is represented by negative num-
bers (reduction in symptoms). For EORTC QLQ-C30 
functioning and symptom subscales that are not shown, 
there only were minimal between-group differences (i.e., 
a difference of <10 points in the mean change in scores 
between the ruxolitinib group and the best-available-
therapy [BAT] group at weeks 24 and 48). The ranges 
for minimal clinically important differences for the 
FACT-Lym are as follows: FACT-Lym total score, 6.5 to 
11.2; FACT-TOI score, 5.5 to 11; FACT-G total score,  
3 to 7; and LymS score, 2.9 to 5.4.19,20
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brosis-associated symptoms (Fig. 2C). In the group 
receiving the best available therapy, FACT-Lym 
scores consistently worsened throughout the study, 
whereas they improved and then stabilized in the 
ruxolitinib group. Patients in the ruxolitinib group 
had a greater improvement in physical condition 
and functioning, as assessed by FACT-TOI scores, 
than did patients in the group receiving the best 
available therapy.
Safety
Both ruxolitinib and the best available therapy were 
associated with few grade 3 or 4 nonhematologic 
adverse events, regardless of whether they were 
thought to be related to the study drug (Table 2), 
and the percentage of patients who discontinued 
treatment owing to adverse events was small in 
both groups (8% in the ruxolitinib group and 5% 
in the best-available-therapy group). The most 
frequently reported nonhematologic adverse event 
of any grade in the ruxolitinib group was diar-
rhea (with diarrhea of any grade occurring in 
23% of the patients and grade 3 or 4 diarrhea 
occurring in 1%); diarrhea was also the only ad-
verse event with a difference in incidence of 10% 
or more between the ruxolitinib group and the best-
available-therapy group. Peripheral edema was the 
most frequently reported adverse event in the group 
receiving the best available therapy. The most fre-
quently reported grade 3 or 4 nonhematologic ad-
verse events were abdominal pain in the ruxolitinib 
group (occurring in 3% of the patients) and dys-
pnea and pneumonia in the group receiving the 
best available therapy (each occurring in 4% of the 
patients). The patients in the ruxolitinib group had 
a mean gain in body weight of 4.43 kg by week 
48, whereas the mean body-weight gain in the best-
available-therapy group was minimal (0.03 kg).
Thrombocytopenia and anemia occurred more 
frequently in the patients receiving ruxolitinib than 
in those receiving the best available therapy (Table 
3), a finding that is consistent with the known 
mechanism of action of ruxolitinib, but these 
events rarely led to treatment discontinuation (one 
patient in each group discontinued the study ow-
ing to thrombocytopenia) and were generally man-
ageable with dose modifications, transfusions of 
packed red cells, or both. Mean hemoglobin levels 
in the ruxolitinib group declined from the baseline 
level of 109.3 g per liter to a nadir of 94.1 g per 
liter at approximately 12 weeks of therapy and then 
increased to a steady state (101.8 g per liter) by 
week 24 (Fig. 2 in the Supplementary Appendix). 
Modifications of the ruxolitinib dose were man-
dated if thrombocytopenia or neutropenia devel-
oped. Adverse events of any grade requiring dose 
reductions or interruptions occurred more fre-
quently with ruxolitinib than with the best avail-
able therapy (in 63% of patients vs. 15%). Throm-
bocytopenia was the most common cause of dose 
modifications in both groups (in 41% of the pa-
Table 2. Nonhematologic and Serious Adverse Events, Regardless of Whether 
They Were Related to the Study Drug.*
Adverse Event
Ruxolitinib
(N = 146)
Best Available Therapy 
(N = 73)
number of patients (percent)
Nonhematologic: all grades, 
grade 3 or 4
Diarrhea 34 (23), 2 (1) 9 (12), 0
Peripheral edema 32 (22), 0 19 (26), 0
Asthenia 26 (18), 2 (1) 7 (10), 1 (1)
Dyspnea 23 (16), 1 (1) 13 (18), 3 (4)
Nasopharyngitis 23 (16), 0 10 (14), 0
Pyrexia 20 (14), 3 (2) 7 (10), 0
Cough 20 (14), 0 11 (15), 1 (1)
Nausea 19 (13), 1 (1) 5 (7), 0
Arthralgia 18 (12), 1 (1) 5 (7), 0
Fatigue 18 (12), 1 (1) 6 (8), 0
Pain in extremity 17 (12), 1 (1) 3 (4), 0
Abdominal pain 16 (11), 5 (3) 10 (14), 2 (3)
Headache 15 (10), 2 (1) 3 (4), 0
Back pain 14 (10), 3 (2) 8 (11), 0
Pruritus 7 (5), 0 9 (12), 0
Serious
Anemia 7 (5) 3 (4)
Abdominal pain 3 (2) 1 (1)
Pyrexia 3 (2) 1 (1)
Esophageal varices 3 (2) 0
Dyspnea 2 (1) 3 (4)
Pneumonia 1 (1) 4 (5)
Actinic keratosis 0 2 (3)
Ascites 0 2 (3)
Peritoneal hemorrhage 0 2 (3)
Respiratory failure 0 2 (3)
* Included are nonhematologic adverse events that occurred in 10% or more of 
patients in either group and serious adverse events that occurred in 2% or 
more of patients in either group.
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tients in the ruxolitinib group and 1% in the best-
available-therapy group). Only 5% of the patients in 
the ruxolitinib group required dose interruptions 
or reductions owing to anemia and 1% owing to 
neutropenia; the corresponding percentages in the 
best-available-therapy group were 1% and 0%.
During the treatment period, more patients in 
the ruxolitinib group than in the best-available-
therapy group received at least one transfusion of 
packed red cells (51% vs. 38%). The mean number 
of transfusions per month was similar in the two 
treatment groups (0.86 and 0.91, respectively). In 
the ruxolitinib group, the percentage of patients 
who required transfusions of packed red cells was 
higher among those who started ruxolitinib at a 
dose of 20 mg twice daily than among those who 
started at 15 mg twice daily (58% vs. 41%).
Serious adverse events were balanced between 
the two groups (Table 2). The most frequently re-
ported serious adverse event in both groups was 
anemia (in 5% of the patients in the ruxolitinib 
group and 4% in the best-available-therapy group). 
Pneumonia was the only serious adverse event re-
ported in 5% or more of patients in either group 
(1% in the ruxolitinib group and 5% in the best-
available-therapy group).
Among the 32 patients who discontinued rux-
olitinib, 19 had adverse events 2 weeks or less after 
discontinuation. Of these 19 patients, 6 patients 
had at least one symptom referable to myelofi-
Table 3. Hemoglobin and Platelet–Count Abnormalities, According to Study Group and Grade.
Laboratory Test and Baseline Grade At Baseline During Study*
Grade 1 Grade 2 Grade 3 Grade 4
number of patients (percent)†
Hemoglobin
Ruxolitinib
Grade 0 43 (29) 17 (12) 17 (12) 4 (3) 0
Grade 1 50 (34) 6 (4) 29 (20) 12 (8) 3 (2)
Grade 2 42 (29) 1 (1) 8 (5) 28 (19) 5 (3)
Grade 3 11 (8) 0 1 (1) 6 (4) 4 (3)
Total 146 (100) 24 (16) 55 (38) 50 (34) 12 (8)
Best available therapy
Grade 0 12 (17) 6 (9) 1 (1) 0 1 (1)
Grade 1 27 (39) 9 (13) 14 (20) 2 (3) 1 (1)
Grade 2 20 (29) 0 12 (17) 6 (9) 2 (3)
Grade 3 10 (14) 0 1 (1) 6 (9) 3 (4)
Grade 4 1 (1) 0 0 1 (1) 0
Total 70 (100) 16 (23) 28 (40) 15 (21) 7 (10)
Platelet count
Ruxolitinib
Grade 0 134 (92) 44 (30) 33 (23) 7 (5) 3 (2)
Grade 1 12 (8) 2 (1) 8 (5) 2 (1) 0
Total 146 (100) 46 (32) 41 (28) 9 (6) 3 (2)
Best available therapy
Grade 0 62 (90) 10 (14) 1 (1) 1 (1) 1 (1)
Grade 1 7 (10) 1 (1) 3 (4) 2 (3) 1 (1)
Total 69 (100) 11 (16) 4 (6) 3 (4) 2 (3)
* Numbers and percentages refer to the highest grade documented during the study. Percentages may not total 100 be-
cause of rounding.
† The denominators for percentages during the study are the total numbers at baseline.
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brosis, including general deterioration in physical 
health (1 patient), pyrexia (2), anorexia (2), fatigue 
(1), weight loss (2), night sweats (1), and pruritus 
(1). Three of these events — general deterioration 
in physical health, pyrexia, and fatigue — were 
reported as grade 3 events. Among the remaining 
patients who discontinued ruxolitinib, there was 
no pattern with respect to the type or severity of 
the event.
At 12 months of follow-up, 10 deaths had been 
reported (6 in the ruxolitinib group [4%] and 4 in 
the best-available-therapy group, [5%]), of which 
7 deaths (4 [3%] and 3 [4%] in the two groups, 
respectively) occurred within 28 days after discon-
tinuation of the study treatment. With an addi-
tional 2 months of follow-up (median total follow-
up, 61.1 weeks), an additional 5 deaths occurred 
in the ruxolitinib group. The causes of death in 
the ruxolitinib group were hepatic failure, cerebral 
hemorrhage, and portal-vein thrombosis after sur-
gery for metastatic squamous-cell carcinoma of 
the head and neck (in 1 patient); pulmonary edema 
and cardiac arrhythmia (1); retroperitoneal hem-
orrhage after an orthopedic procedure (1); intes-
tinal perforation associated with terminal ileitis 
(1); respiratory infection (1); cardiac arrest and 
myelofibrosis (1); cardiac failure (1); pulmonary 
extramedullary hematopoiesis and pulmonary fail-
ure (1); post-transplantation lymphoproliferative 
disorder and multiorgan failure (1); and myelofi-
brosis (2). The causes of death in the best-avail-
able-therapy group were pneumonia, septic shock, 
multisystem organ failure, and acute myeloid 
leukemia (in 1 patient); post-splenectomy Klebsiella 
pneumoniae sepsis (1); splenectomy, peritoneal 
hemorrhage, and respiratory failure (1); and renal 
failure and acute myeloid leukemia (1).
Discussion
This randomized, phase 3 study shows the supe-
riority of a JAK1 and JAK2 inhibitor over the best 
available therapy with respect to clinically relevant 
end points in patients with myelofibrosis. Ruxoli-
tinib resulted in a rapid reduction in splenomegaly 
(at weeks 24 and 48). The meaningful overall reduc-
tions in debilitating symptoms of myelofibrosis 
and improvements in role functioning, which were 
observed by week 8 and continued through week 
48, attest to the beneficial effects of ruxolitinib on 
quality of life in patients with myelofibrosis. In 
addition to these reductions in splenomegaly and 
myelofibrosis-associated symptoms, ruxolitinib re-
sulted in changes in cytokine levels that were simi-
lar to those that have been reported previously15 
and that have been implicated in the clinical pheno-
type of myelofibrosis.21 In contrast, the best avail-
able therapy was associated with a median increase 
in spleen volume and a worsening of symptoms.
Ruxolitinib was associated with increased fre-
quencies of anemia and thrombocytopenia, find-
ings that are consistent with the results of previous 
studies.15,22,23 Anemia and thrombocytopenia 
could generally be managed with dose reductions 
or brief interruptions of ruxolitinib therapy, and 
treatment had to be discontinued in only one pa-
tient in the ruxolitinib group owing to thrombo-
cytopenia and in none owing to anemia. More 
patients in the ruxolitinib group than in the best-
available-therapy group required transfusions of 
packed red cells to treat anemia, though the mean 
number of units transfused per patient was simi-
lar in the two treatment groups.
Some differences in response rates were de-
tected between patients with the wild-type allele 
and those with the JAK2 V617F mutation. However, 
the overall similarity in responses across sub-
groups suggests that these factors may not be use-
ful prerequisites for the consideration of ruxoli-
tinib therapy. Longer follow-up will be needed to 
assess changes in marrow fibrosis and the JAK2 
V617F allele burden.
Although no benefit of ruxolitinib was observed 
with respect to overall survival, at the updated 
analysis, approximately 25% of the patients who 
had been assigned to receive the best available 
therapy had crossed over to ruxolitinib, and an 
additional 12% had withdrawn consent, with no 
additional follow-up for survival. This limits the 
interpretation of the survival analysis because of 
confounding survival data for one third of the 
patients in the best-available-therapy group.
In summary, this study shows that continuous 
oral ruxolitinib therapy can reduce splenomegaly 
and improve quality of life in patients with myelo-
fibrosis. Further follow-up is needed to assess the 
long-term outcomes with respect to efficacy and 
safety.
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